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Abstract
We applied customized targeted next-generation exome sequencing (NGS) to determine if mutations in genes associated
with renal malformations, Alport syndrome (AS) or nephrotic syndrome are a potential cause of renal abnormalities in
patients with equivocal or atypical presentation. We first sequenced 4,041 exons representing 292 kidney disease genes in a
Caucasian woman with a history of congenital vesicoureteral reflux (VUR), recurrent urinary tract infections and
hydronephrosis who presented with nephrotic range proteinuria at the age of 45. Her biopsy was remarkable for focal
segmental glomerulosclerosis (FSGS), a potential complication of longstanding VUR. She had no family history of renal
disease. Her proteinuria improved initially, however, several years later she presented with worsening proteinuria and
microhematuria. NGS analysis revealed two deleterious COL4A3 mutations, one novel and the other previously reported in
AS, and a novel deleterious SALL2 mutation, a gene linked to renal malformations. Pedigree analysis confirmed that COL4A3
mutations were nonallelic and compound heterozygous. The genomic results in conjunction with subsequent abnormal
electron microscopy, Collagen IV minor chain immunohistochemistry and progressive sensorineural hearing loss confirmed
AS. We then modified our NGS approach to enable more efficient discovery of variants associated with AS or a subset of
FSGS by multiplexing targeted exome sequencing of 19 genes associated with AS or FSGS in 14 patients. Using this
approach, we found novel or known COL4A3 or COL4A5 mutations in a subset of patients with clinically diagnosed or
suspected AS, APOL1 variants associated with FSGS in African Americans and novel mutations in genes associated with
nephrotic syndrome. These studies demonstrate the successful application of targeted capture-based exome sequencing to
simultaneously evaluate genetic variations in many genes in patients with complex renal phenotypes and provide insights
into etiology of conditions with equivocal clinical and pathologic presentations.
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potentially guide therapy. However, their application to kidney
disease has been limited.
We first analyzed exomes of several hundred genes using a
targeted customized exome sequencing approach in a patient with
a history of vesicoureteral reflux (VUR) who presented with
proteinuria and FSGS on renal biopsy. We identified two
deleterious nonallelic COL4A3 mutations, one novel and the other
previously reported in an Alport syndrome (AS) patient. We
further identified a deleterious mutation in SALL2, a gene
important in early kidney development. Pedigree analysis
confirmed that the COL4A3 mutations were compound heterozygous and subsequent clinical work-up confirmed dual disease,
Alport syndrome and VUR. We then applied a modified targeted
exome sequencing by multiplexing 19 genes and 14 patients with

Introduction
Glomerular dysfunction is the most common cause of end
stage renal disease [1,2]. Damage to the glomeruli can manifest
in a number of ways including proteinuria, hematuria and
hypertension [1,3,4,5,6,7]. Many glomerular diseases are categorized according to well-defined histopathological patterns. For
example, focal segmental glomerulosclerosis (FSGS) pattern in a
biopsy can be caused by different etiologies including primary
or secondary glomerular disease or reflux due to lower urinary
tract malformations [8]. Newer genomic technologies including
next-generation sequencing (NGS) are rapidly evolving and may
provide new insights into disease pathogenesis, diagnosis,
genetics or prognosis, explain histopathological findings and
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were done by the Washington University Kidney Translational
Research Core. Samples from 15 patients were used (14
glomerular disease, 1 glomerular and renal malformation).

either well established or clinically suspected AS or FSGS to
determine potential genetic cause of their diseases. Several novel
and previously known COL4A mutations in AS, APOL1 G2
deletion variants in some FSGS patients and new coexisting gene
mutations in proteinuria related genes (LAMA5) were identified.
These studies are among the first to apply Next-gen targetedcapture exome sequencing approach in delineating genetic basis
for atypical and complex renal diseases presenting as renal
malformations and/or glomerular diseases.

Gene Selection
The genes selected for this study resulted from searches of public
databases such as PUBMED and GUDMAP (http://www.
gudmap.org/) and abstracts as of 2010 (Figure 1a). Briefly, search
terms included genes associated with CAKUT and/or other
kidney related phenotypes such as renal failure, abnormal kidney
development, ectopic kidney, atrophic kidney, single kidney, no
kidney, and kidney disease. The gene lists were further curated
based on their expression patterns, functional significance in
disease models and mutations in human kidney disease. A total of
292 genes comprising 4,041 exons were selected for the
sequencing studies (Table S1). The genomic intervals for the

Materials and Methods
Human Studies
Human studies were conducted according to protocols approved by the Washington University human research protection
office. Patient recruitment, specimen collection and processing

Figure 1. Overview of the targeted exome sequencing pipeline and filtering strategy applied to patient with VUR and proteinuria.
(A) Criteria for gene selection for developing a custom targeted renal disease exome array. (B) Custom-exome capture sequencing metrics from the
patient 1184405 and filtering approach used to identify four novel mutations in three kidney disease genes.
doi:10.1371/journal.pone.0076360.g001
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Figure 2. Validation and evolutionary conservation of the identified mutations in the patient with VUR and proteinuria. (A) Sanger
sequencing analysis confirms the novel COL4A3 mutations, COL4A3_G/A_G695R and COL4A3_T/C_L1474P, the SALL2_G/C_G792R and the MYH9_C/
T_L46F mutations in the patient 1184405. (B) Multi species alignment shows that both the COL4A3 mutation reference amino acids Col4A3_ 695_G
and Col4A3_1474_L, the SALL2_G792R and the MYH9_L46F are highly conserved among species. (C) Schematic representation of Human COL4A3 gene
with the discovered mutations in patient 1184405. The domains are: signal peptide domain (red), the N terminal 7S domain (blue), the central triple
helix collagenous (COL) domain (green) and the carboxy-terminal non-collagenous (NC1) domain (yellow).
doi:10.1371/journal.pone.0076360.g002

Library preparation tool of Agilent for paired end sequencing. The
final library generated consisted of 57,576 total functional baits
that cover 3,454,560 bp of the genome. For the screening of
mutations in patients with proteinuria or AS multiplexed targeted
exome capture and NGS was done on a set of 19 genes
(Supplemental Table S3) known or predicted to be associated
with AS or proteinuria. Gene selections and library preparation
were same as described above.

shortlisted genes were selected using GRch37/hg19 version of the
assembled human genome. The UCSC genome browser (http://
genome.ucsc.edu/cgi-bin/hgTables?org = Human&db =
hg19&hgsid = 192997943&hgta_doMainPage = 1) was used to
obtain the start and end sites of each exon including known
isoforms and 75 bp of flanking regions were additionally included
to cover the exon-intron boundaries and the splice junctions. In
some cases, 10 Kb promoter regions were also included; however,
this analysis was focused on exons and flanking sequences.

Custom Bait Library Generation

DNA Extraction, Library Preparation, Next-generation
Sequencing and Data Filtering

Bait generation and library preparation were done using the
eArray tool provided by the manufacturer (Agilent technologies,
(https://earray.chem.agilent.com/earray)). The baits, 120 bp
each, were generated for Illumina end sequencing technology
with bait tiling frequency of 2X using optimized parameters. The
failed baits (632) were redesigned with the repeatmasker filter
turned off. We also included baits for sequencing 815 miRNA that
were already predesigned by Agilent. Library was created using

Genomic DNA was obtained from the Washington University
Kidney Translational Research Core. Briefly, genomic DNA was
isolated from peripheral blood leukocytes using QIAamp DNA
blood mini kit (Cat No 51106) according to manufacturer’s
instructions. Genomic DNA for relatives was isolated from buccal
cells using an over the counter mouthwash (Scope). For the
patients with AS and CAKUT, library preparation targeted
capture against the baits and NGS using GAIIx sequencer
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Figure 3. Pedigree analysis of the index patient with proetinuria and VUR. (A) Pedigree of the family of the index patient (1184405, arrow)
shows presence of Col4A3_T/C_L1474P variant in one unaffected brother (4302442) and nephew (4302444), but absent in the unaffected sister
(4302445) and niece (4302443); while the other damaging variant Col4A3_G/A_G695R is present only in the patient. The SALL2 deleterious mutation
SALL2_G/C_G792R is present in the patient and one unaffected brother (4302442) while the MYH9_C/T_L46F mutation is present in all but one
affected family member (4302445). (B) Sanger sequencing analysis confirms the status of the novel COL4A3 mutations Col4A3_G/A_G695R and
Col4A3_C/T_L1474P, and the SALL2_G/C_G792R and MYH9_C/T_L46F mutations in the relatives of patient 1184405. The Col4A3_T/C_L1474P
heterozygous variant was present in one unaffected brother (4302442) and nephew (4302444), but absent the unaffected sister (4302445) and niece
(430443). The mutation Col4A3_G/A_G695R was absent in all other family members. The SALL2_G/C_G792R mutation was present only in the
unaffected brother 4302442 while the MYH9_C/T_L46F mutation was more common and was present in everyone except the unaffected sister
4302445.
doi:10.1371/journal.pone.0076360.g003

authorized to conduct human studies. Genotype data will be
deposited at the European Genome-phenome Archive (EGA,
http://www.ebi.ac.uk/ega/), which is hosted by the EBI, under
accession number EGAS00001000560.

(Illumina) was done by the Genome Technology Access Center
core facilities.
Novoalign (http://www.novocraft.com) was used for alignment
of the sequencing reads and variant calling was done using SAM
tools [9] as described before [10]. SNP calls were filtered against
the dbSNP129 database, in-house exome data and prioritized
according to importance with publicly available software tools
(Figure 1b). The effect of amino acid substitution on protein
function was predicted with Sorting Intolerant from Tolerant
(SIFT, http://sift.jcvi.org/) and Polymorphism Phenotyping v2
(PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/) [11]. Controlled access to sequencing data are available to investigators

PLOS ONE | www.plosone.org

Sanger Sequencing
Novel or rare variants identified from exome sequencing in the
patient with VUR and proteinuria were validated using Sanger
sequencing. All primers used are shown in Supplemental Table
S2. Sanger sequencing was performed in the tissue procurement
and molecular phenotyping core at the Washington University.
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Figure 4. Results of immunostaining with antibodies against a1, a3, and a5 chains of type IV collagen in the AS/VUR patient. (A)
ColIVa1 expression is strong and consistent in the basement membranes (BM) of the glomeruli and the tubules; typically it is absent in adult
glomeruli. Images show absent a3IV (B) and weak a5IV (C) staining in the glomerular BMs. (D&E) Electron micrograph from this patient shows
segmental glomerular basement membrane (GBM) lamellation and outpouching (D arrow) and irregular thickening (E arrow) of the GBM
characteristic of AS. COL4a3 immunostaining in control shows the normal tubular and capillary loop distribution for comparison (F).
doi:10.1371/journal.pone.0076360.g004

disease. At age 48 she presented with worsening proteinuria, her
repeat biopsy showed FSGS, and the electron microscopy findings
were suggestive of hereditary nephritis. The patient consented to
participate in studies to investigate potential molecular-genetic
causes of her kidney disease that may help clarify or provide
insights into the underlying etiology of her renal dysfunction.

The data were analyzed using DNASTAR software (http://www.
dnastar.com/).

Histopathology
Histopathological results were obtained from the Pathology
archives of Washington University School of Medicine in St. Louis
and Cornell University. These data were part of routine care
involving light microscopy, immunohistochemistry and electron
microscopy of renal biopsies.

Deleterious Mutations in COL4A3, MYH9 and SALL2 in the
Patient 1184405
To identify gene defects that may uncover potential cause of
CAKUT or proteinuria that lead to kidney dysfunction in the
patient 1184405 we sequenced the coding region and exon-intron
splice junctions of 292 genes most likely associated with renal
anomalies or glomerular disease using NGS (see methods).
Sequencing results showed high depth of coverage with more
than 90% of the targeted region sequenced at a depth of 8-fold or
greater (Figure 1b). To prioritize identification of mutations that
are the most deleterious we adopted a filtering strategy to focus on
non-synonymous novel deleterious variants using a combination of
filtering against SNP databases, in-house unrelated non-kidney
disease exomes and bioinformatic software tools Polyphen2 and
SIFT (Figure 1b) [10]. We discovered four novel non-synonymous
mutations: COL4A3_G695R, COL4A3_L1474P, MYH9_L46F and
SALL2_G792R that were all predicted to be damaging (Figure 1b).
All four mutations were confirmed by Sanger sequencing
(Figure 2a). Bioinformatic analysis revealed that the mutated
residues were conserved across species (Figure 2b). The COL4A3
mutations were in a highly conserved glycine rich region and in an
important functional domain (Figure 2c).

Sanger Sequencing Validation of the APOL1 Deletion in
African American Focal Segmental Glomerulosclerosis
(FSGS) Patients
To confirm the APOL1deletion variation (rs71785313), also
known as G2, in the two African American (AA) FSGS patients,
Sanger sequencing was performed using the APOL1_I/
D_rs71785313 primer set (Supplemental Table S2). The same
primer set was used to determine the allelic frequency of the
deletion in a set of African-American FSGS patients and unrelated
controls.

Results
Clinical Phenotype of a Patient with Unexplained
Proteinuria
We enrolled a Caucasian woman (patient 1184405) whose past
medical history is significant for vesicoureteral reflux (VUR)
diagnosed at age two, several urinary tract infections and
hydronephrosis. At age 45 she presented with nephrotic range
proteinuria and hypertension but no evidence of hematuria. Her
kidney biopsy showed histopathologic changes that suggested focal
segmental glomerulosclerosis (FSGS), however, immunohistochemical and electron microscopy studies were inconclusive. She
has no family history of renal disease. Her proteinuria initially
improved on oral steroids but later required additional immunosuppressants due to worsening creatinine; proteinuria range was
2+ to 3+. It was unclear from the clinical course if the patient had
primary or secondary FSGS, for example, due to VUR or another
PLOS ONE | www.plosone.org

Pedigree Analysis of the Four Deleterious Mutations in
Patient 1184405
The presence of COL4A3 mutations suggested Alport syndrome
in this patient as a likely cause of proteinuria (see below). We next
performed studies to determine the inheritance pattern of the
deleterious mutations found in patient 118405. Consent was
obtained from the available family members (Figure 3). Sanger
sequencing was performed on their genomic DNA to detect
5
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Table 1. Clinical characteristics of patients that underwent validation of custom multindexed targeted exome sequencing of 19 genes.

biospy inconclusive
(proteinuria)

normal COL4A5 (HTN)

no biopsy (inc Cr, HTN)
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Targeted Exome Sequencing in Alport Syndrome

October 2013 | Volume 8 | Issue 10 | e76360

Targeted Exome Sequencing in Alport Syndrome

COL4A3-G695R and COL4A3-L1474P mutations. None of the
family members harbored both COL4A3 mutations suggesting the
possibility that they are on separate alleles in the index patient
(Figure 3a,b). The COL4A3-L1474P mutation was found in an
unaffected brother and his son with unknown disease status. The
COL4A3-G695R mutation was not present in any of the family
members studied indicating the possibility of a de novo change.
Mutation analysis of SALL2 and MYH9 was also performed by
Sanger sequencing in all the available family members and none of
the family members harbored all four mutations (Figure 3a and
3b).

predicted to be probably damaging using the PolyPhen 2 software
(Table 1). No small indels or exon deletions were present in the
Collagen 4A3, A4 or A5 genes. Visual inspection of the mutations
identified by SAMtools confirmed the base calls made. We also
detected a previously reported 6 bp deletion in APOL1 (G2
variant) that is associated with the development of FSGS in
African Americans [12] and verified this variant using Sanger
sequencing.

Discussion
We applied targeted custom exome capture and next-generation sequencing and identified known and/or novel variants in
patients with complex kidney disease or where clinicopathological
and genetic correlations were discordant. We first applied our
strategy to a 54 year old patient with congenital VUR who
presented with heavy proteinuria and diagnosis of FSGS. We
discovered COL4A3 mutations that in conjunction with subsequent
clinical, family and pathological data undoubtedly identify her as
an index case of atypical presentation of AS. We also identified a
deleterious SALL2 mutation as a potential cause of her VUR and
an unexpected novel MYH9 mutation in the same patient. These
results demonstrated the power of targeted exome sequencing on
selected genes simultaneously to help understand a complex
kidney phenotype in a patient and diagnose AS in the absence of
typical symptoms or family history. We further showed that this
approach is suitable for screening for mutations in selected genes
that are associated with glomerular disorders in patients suspected
to have AS or FSGS clinically, or detection of G1 or G2 APOL1
variants in African Americans. The studies suggest that sequencing
of a defined set of genes in patients with glomerular diseases or
CAKUT may help in early diagnosis and management particularly in complex cases.
We selected several hundred genes important in kidney
development and glomerular diseases to identify mutations that
may provide insights into the presence of a congenital anomaly
(VUR, hydronephrosis) and proteinuria in a patient where the
etiology of either entity was unclear since FSGS pattern can be
observed in obstructive or reflux nephropathy or primary
glomerular diseases. Sequencing of these candidate genes most
likely associated with kidney defects and proteinuria revealed 2
mutations in COL4A3 gene, a gene associated with Alport
syndrome and SALL2, a gene associated with urinary tract
development. Genomic studies confirmed AS in the index patient
with no family history of kidney disease, late age of onset, heavy
proteinuria, and no hematuria on initial presentation. The patient
developed hematuria, sensorineural hearing loss and showed
pathological findings characteristic of AS several years after the
initial onset of proteinuria. Dysfunction of any of the threecollagen IV genes, COL4A3, COL4A4 and COL4A5, disrupts
proper heterotrimer formation resulting in failure to deposit
normal collagen matrix in the glomerular basement membrane
and disruption of the filtration barrier. Absence of COL4A3 and
COL4A5 immunolabeling in the patient’s biopsy further confirmed
that the COL4A3 mutations are causative. Pedigree analysis
indicated that the two COL4A3 mutations are on different alleles
and compound heterozygous. About 15% of AS cases are thought
to exhibit autosomal recessive mode of inheritance [13]. Two of
this patient’s relatives had COL4A3-L1474P mutation. Whether
the second COL4A3-G695R mutation occurred de novo or was
inherited is unclear as the samples from the parents were not
available. The relatives with the mutations are reportedly healthy
indicating that presence of both the mutations is necessary for
developing the disease or there could be other modifiers. In this

Immunohistochemistry and Electron Microscopy Confirm
Collagen Defects
At age 52 the patient [1184405] presented with proteinuria (3+)
and hematuria (1+) and reported hearing loss of two years
duration. A kidney biopsy was performed to confirm hereditary
nephritis (AS) as a cause of her worsening renal dysfunction. Light
microscopy was remarkable for FSGS. We performed COL4a1,
COL4a3 and COL4a5 immunohistochemistry and found strong
COL4a1 immunoreactivity in the glomerular capillary loops, and
tubular basement membrane, weak COL4a5 in glomerular
capillary loops and basement membrane of distal tubules and no
COL4a3 immunoreactivity (Figure 4). EM showed glomerular
basement membrane thickening and laminations alternating with
areas of thinning, findings consistent with AS.

Custom Next-generation Sequencing of Candidate
Proteinuria Genes Simultaneously in Several Patients
(Multi-indexed) Provides Genetic Evidence for Cause of
Alports or FSGS
We next extended our above analysis to a modified NGS
approach to identify mutations in a selected group of genes
associated with proteinuria in patients with clinically diagnosed
Alports or FSGS or cases in which diagnosis was equivocal (see
Table 1 for patient characteristics). We sequenced coding region of
a set of 19 genes (Supplementary Table 3) in nine patients with a
clinical diagnosis of hereditary nephritis or AS and five FSGS
patients. One of the patients with FSGS diagnosis (07-0430-01590)
is a relative of another patient with AS (07-0430-02009). As
indicated in Table 1, some of these patients had established AS
based on family history or pathological findings while in others
there was a family history of kidney disease but no pathologically
or genetically confirmed AS. The FSGS patients were selected to
serve as negative controls for COL4 mutations and to determine if
variations in genes associated with proteinuria may explain the
etiology in some of these patients. We applied a multiindexing
approach where each patient’s DNA was coded with a unique tag
(index) so the targeted exomes from all the patients could be
simultaneously sequenced. NGS metrics revealed greater than
200-fold average coverage and 95% of the region of interest was
covered at a depth of 40X or greater (Supplementary table 4).
Using the same filtering approach as for the patient with Alports
and VUR above we found COL4A3, COL4A4 and/or COL4A5
novel or rare mutations in 6 out of 9 unrelated patients with
known or equivocal AS and novel LAMA5 mutations in 3 out of 4
FSGS patients (Table 1). Two relatives (07-0430-02009 and 070430-01590) were included and the same COL4A5-G1161E
mutation was independently identified providing credence to our
approach. Among these, patient 07-0430-01590 is the grandmother of 07-0430-02009 and did not previously have AS
diagnosis and is clinically phenotyped as FSGS. Based on
bioinformatics predictions a number of these variants were
PLOS ONE | www.plosone.org
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regard, it was interesting that this patient also had a MYH9-L46F
mutation. Mutations in MYH9 have been associated with hearing
disorders, kidney defects and thrombocytopenia [14,15]. We
found that the patient’s platelet volume was low, but she did not
have thrombocytopenia. Since some of the features of AS [16,17]
and patients with MYH9 mutations overlap, it is possible that this
patient disease phenotype is a result of interactions between these
two genes. No other family members had all three mutations
suggesting that only collectively they are penetrant. While both
SALL2 and MYH9 mutations likely contribute to the complex
phenotype in this patient, biological studies using model systems
would be needed to support if these are sufficient or necessary for
the phenotype observed. Early onset AS is often associated with
large exon deletions, nonsense mutations or splice site changes.
The patient had late onset of glomerular disease, which is
consistent with the missense COL4A mutations.
Early diagnosis of AS, a rare disorder with frequency of
1:50,000, is clinically important for counseling and clinical
management. Existing common methods to diagnose AS include
DHPLC and Sanger sequencing. However the large gene size and
high number of exons in each of the COL4 family genes (51 in
COL4A5, 48 in COL4A4 and 52 in COL4A3), and absence of any
mutation hotspot poses difficulties in timely diagnosis and is costly
for researches interested in delineating pathogenetic mechanisms.
Recently Artuso et al., applied amplicon based NGS of just the
COL4A3 genes in AS [18]. While this approach is preferable to the
older methods, in atypical cases and in cases where pathology is
equivocal such as segmental COL4A3, 4 or 5 staining or
insufficient material, information on additional genes (several
hundred or less than 30) that may be contributing is needed. Our
approach is more efficient and economical as the dynamic range of
number of genes to be surveyed can be easily scaled and it allows
for indexing (see below) where several patients or family members
can be simultaneously evaluated.
Our multiplexed NGS experiments were conducted on 14
patient samples with 19 genes commonly associated with AS or
FSGS including steroid resistant nephrotic syndrome. The
advantage was that all samples could be simultaneously sequenced
and analyzed for variations in these genes at an average read depth
of 200X thus significantly increasing the efficiency of obtaining
sequence data. We find this approach preferable when the focus is
evaluation of small number of genes as an underlying cause of a
clinical condition. We focused on AS and included patients with
well-documented clinical history and diagnosis. We also included
some patients with presumed diagnosis of hereditary nephritis or
family history of kidney disease. Our customized exome capture
array harbored a subset of genes associated with AS and nephrotic
syndrome and confirmed known or novel mutations in COL4A3,
A4 or A5 in four of the five AS patients. Some patients did not
have established family history of AS. In two of these patients, we
successfully identified novel or known variants that explain their
disease. The patients in whom we did not identify deleterious
COL4A mutations suggest either that these patients need reevaluation of clinical diagnosis or there are changes in COL4A gene
structures that were not identified here. For example, structural
changes in the genome and changes in non coding regions will be
missed with current method. FSGS patients were included to serve
as negative control for AS and to identify any new mutations in
FSGS associated genes. The discovery of novel variants in the

LAMA5 gene has not been reported before. Interestingly three out
of five FSGS patients had a novel LAMA5 mutation predicted to
be deleterious. LAMA5 is important in maintaining the glomerular
filtration barrier integrity [19]; however to our knowledge it has
not been associated with FSGS previously. Two of the FSGS
patients also harbor mutations in PLCE1, NPHS1 and ACTN4
genes respectively. These genes are associated with FSGS
[20,21,22,23] and suggesti that these variants contribute to the
disease. It is possible that some of these could be neutral or
beneficial or deleterious mutations. We have included prediction
scores (Table 1), but unequivocal proof of causation versus neutral
variations would require efficient biological validation strategies.
Our methods also successfully identified variants that are
associated with FSGS in African Americans further portraying
the versatile application of NGS in diagnoses and discovery of
variants associated with AS or FSGS.
The candidate gene capture and NGS approach we applied is
robust in identifying deleterious mutations in different kidney
diseases and more importantly if these mutations can provide
insights into disease process. This is the first application of this
approach to a complex kidney disease presentation and AS, and
detecting defined variants associated with FSGS or Alports. Our
study demonstrates an integrated approach that utilizes biological
and clinicopathologic information in screening defined set of genes
for gleaning insights into disease etiology using NGS. These
strategies should pave the way to clinical sequencing and high
throughput mutation discovery studies compared to single gene
approaches that are now inefficient and costly.
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